ArticleFunctional & integrative genomics2026
Mitochondrial metabolism-associated biomarkers in oral lichen planus and oral squamous cell carcinoma.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral lichen planus (OLP), a chronic inflammatory condition, is classified as a potentially malignant disorder due to its risk of progression to oral squamous cell carcinoma (OSCC). Mitochondrial metabolism plays a key role in pathogenesis and progression of OSCC. This study aimed to identify and validate biomarkers associated with mitochondrial metabolism-related genes (MRGs) in OLP and OSCC, thereby contributing to the development of novel therapeutic strategies. Transcriptomic data from OLP (GSE38616, GSE52130) and OSCC (GSE30784, GSE25099) datasets were analyzed. Differentially expressed genes were intersected with known MRGs to identify candidate biomarkers. These genes were further validated through expression analyses within the respective datasets. A predictive nomogram was constructed based on selected biomarkers and assessed for diagnostic performance. Functional enrichment analysis, immune cell infiltration profiling, pharmacological targeting prediction, molecular docking, and reverse transcription quantitative PCR (RT-qPCR) validation were performed to elucidate underlying biological mechanisms. Three biomarkers ALDH3A2, CYP11A1, and IMPDH2 were identified as significantly associated with both OLP and OSCC. Expression levels of these genes were significantly reduced in affected tissues compared to unaffected control tissues, a finding confirmed through RT-qPCR analysis. A nomogram incorporating these biomarkers effectively predicted OSCC risk. Functional enrichment analysis indicated co-enrichment of these genes in the olfactory transduction pathway in OLP and the ECM-receptor interaction pathway in OSCC. Analysis of immune infiltration identified 22 differentially abundant immune cell types in OSCC versus control samples, with ALDH3A2 exhibiting a strong inverse correlation with natural killer T cell levels. A total of 29 candidate compounds targeting these biomarkers were identified; among them, IMPDH2 presented a binding energy of - 10.6 kcal/mol with AC1NRCGS, indicating potential therapeutic relevance. ALDH3A2, CYP11A1, and IMPDH2 were validated as potential biomarkers linked to mitochondrial metabolism in patients with OLP and OSCC. These findings provide a foundation for further exploration of targeted treatment strategies in the management of OLP and OSCC.
Indexed as
Identifiers
42418018What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.